G&E Herbal Biotechnology Co., Ltd. (TPEX:4911)
Taiwan
· Delayed Price · Currency is TWD 47.75
-0.15 (-0.31%)
Dec 5, 2025, 1:02 PM CST
G&E Herbal Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | 143.1 | 102.06 | 72.4 | 7.38 | -19.88 | -14.3 | Upgrade
|
| Depreciation & Amortization | 10.55 | 10.38 | 9.33 | 9.4 | 9.33 | 9.21 | Upgrade
|
| Other Amortization | - | - | - | - | 0 | 0 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | 0.01 | 0.01 | 0 | 0.02 | 0.01 | Upgrade
|
| Other Operating Activities | 13.59 | 22.5 | 17.98 | 0.71 | 1.67 | -2.51 | Upgrade
|
| Change in Accounts Receivable | -3.13 | -3.04 | -14.19 | 4.38 | 1.08 | -2.22 | Upgrade
|
| Change in Inventory | -6.15 | 1.2 | 1.74 | -5.69 | -2.85 | 0.14 | Upgrade
|
| Change in Accounts Payable | 0.28 | 1.42 | -2 | 2.47 | -0.35 | 0.35 | Upgrade
|
| Change in Unearned Revenue | 5.17 | -10.01 | 23.39 | 71.39 | 0.28 | 0 | Upgrade
|
| Change in Other Net Operating Assets | 6.46 | 10.16 | 4.82 | 9.92 | 1.52 | 10.09 | Upgrade
|
| Operating Cash Flow | 169.87 | 134.68 | 113.48 | 99.96 | -9.19 | 0.77 | Upgrade
|
| Operating Cash Flow Growth | 44.62% | 18.68% | 13.52% | - | - | - | Upgrade
|
| Capital Expenditures | -4.24 | -5.92 | -5.52 | -2.95 | -1.77 | -5 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.01 | -0.08 | - | -0.01 | -0.22 | -1.77 | Upgrade
|
| Investment in Securities | -95.61 | -83.05 | -82.04 | 5.4 | 9 | 15.9 | Upgrade
|
| Other Investing Activities | - | -0.19 | -0.87 | 0.07 | - | -0.01 | Upgrade
|
| Investing Cash Flow | -99.86 | -89.24 | -88.43 | 2.51 | 7.01 | 9.13 | Upgrade
|
| Long-Term Debt Repaid | - | -0.77 | -0.12 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -0.87 | -0.77 | -0.12 | - | - | - | Upgrade
|
| Common Dividends Paid | -44.66 | -31.76 | - | - | - | - | Upgrade
|
| Financing Cash Flow | -45.53 | -32.54 | -0.12 | - | - | - | Upgrade
|
| Net Cash Flow | 24.48 | 12.9 | 24.94 | 102.47 | -2.18 | 9.9 | Upgrade
|
| Free Cash Flow | 165.63 | 128.76 | 107.96 | 97.01 | -10.96 | -4.23 | Upgrade
|
| Free Cash Flow Growth | 49.61% | 19.26% | 11.29% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 53.12% | 51.70% | 59.50% | 150.15% | -44.61% | -14.98% | Upgrade
|
| Free Cash Flow Per Share | 2.60 | 2.02 | 1.69 | 1.52 | -0.17 | -0.07 | Upgrade
|
| Cash Interest Paid | 0.04 | 0.04 | 0 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 6.72 | 0.15 | 0.02 | - | - | - | Upgrade
|
| Levered Free Cash Flow | - | 82.35 | 67.88 | 93.19 | -5.52 | -7.17 | Upgrade
|
| Unlevered Free Cash Flow | - | 82.37 | 67.88 | 93.19 | -5.52 | -7.17 | Upgrade
|
| Change in Working Capital | 2.63 | -0.28 | 13.76 | 82.47 | -0.32 | 8.36 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.